Safety, Tolerability, and Efficacy of Azilsartan Medoxomil With or Without Chlorthalidone During and After 8 Months of Treatment for Hypertension

A phase 3, 26‐week, open‐label, titrate‐to‐target study (n=418) assessed the safety of azilsartan medoxomil (AZL‐M) alone and with chlorthalidone (CLD), followed by a 6‐week, double‐blind, placebo‐controlled reversal phase with change in clinic diastolic blood pressure (DBP) as the primary endpoint....

Descripción completa

Detalles Bibliográficos
Autores principales: Kipnes, Mark S., Handley, Alison, Lloyd, Eric, Barger, Bruce, Roberts, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024056/
https://www.ncbi.nlm.nih.gov/pubmed/25619410
http://dx.doi.org/10.1111/jch.12474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024056/
https://www.ncbi.nlm.nih.gov/pubmed/25619410
http://dx.doi.org/10.1111/jch.12474

Ejemplares similares